A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Platform Study Evaluating the Efficacy and Safety of Interventions in Participants with Moderately to Severely Active Crohn s Disease

Brief description of study

The primary objective is to evaluate the efficacy of JNJ-active compunds as measured by the change in the Crohn’s Disease Activity Index (CDAI) score and Simplified Endoscopic Score for Crohn’s disease (SES-CD) from baseline at Week 12. This allows you the chance to receive one of the investigational treatments being researched for people with Crohn’s disease, faster.


Clinical Study Identifier: s17-00190
ClinicalTrials.gov Identifier: NCT04102111


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.